75 results
8-K
ATHA
Athira Pharma Inc
17 May 24
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
5:00pm
settlement calls for the Company to adopt certain corporate governance reforms and pay lead plaintiffs’ attorney’s fees, litigation expenses, and lead
8-K
EX-99.1
ATHA
Athira Pharma Inc
17 May 24
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
5:00pm
settlement calls for Athira to adopt certain corporate governance reforms and pay lead plaintiffs’ attorney’s fees, litigation expenses, and lead
8-K
EX-99.1
ATHA
Athira Pharma Inc
15 May 24
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
4:10pm
the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation
PRE 14A
ug7v wwp3f1rxu
28 Mar 24
Preliminary proxy
8:47am
S-8
lqoaw5h
22 Feb 24
Registration of securities for employees
4:34pm
8-K
EX-99.1
0x8nziudqsj3cnwevp9
22 Feb 24
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
4:10pm
8-K
EX-99.1
0sbvtna2av
8 Jan 24
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
7:11am
8-K
EX-99.1
f9733ey
9 Nov 23
Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates
4:10pm
8-K
EX-99.1
e2v8apjx mprfse0
10 Aug 23
Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates
4:10pm
8-K
EX-99.1
vyrz vez6f0vrp66uejf
22 May 23
Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer
8:00am
8-K
EX-10.3
92cubti
22 May 23
Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer
8:00am
8-K
EX-99.1
elwywnft
11 May 23
Athira Pharma Reports First Quarter 2023 Financial Results
4:11pm
8-K
EX-99.1
54ck3dt
10 Nov 22
Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
4:11pm